Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 11/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CBLB | Q13191 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15673525 | 0.85 | GSK3B (0.39) | GSK3BCYP2D6 | |
| SCHEMBL3274219 | 0.82 | GSK3B (0.49) | GSK3BNPC1RAB9ACYP2D6 | |
| SCHEMBL3274906 | 0.80 | GSK3B (0.42) | GSK3BCYP3A4CYP2D6 | |
| SCHEMBL3145032 | 0.79 | GSK3B (0.41) | GSK3BCBLBCYP3A4CYP2D6 | |
| SCHEMBL3273819 | 0.79 | GAA (0.53) | GSK3BNPC1RAB9ACYP2D6 | |
| SCHEMBL3275008 | 0.77 | RECQL (0.44) | GSK3BCYP2D6 | |
| SCHEMBL15673522 | 0.76 | GSK3B (0.45) | GSK3BCYP2D6 | |
| SCHEMBL3275516 | 0.75 | GSK3B (0.42) | GSK3BCYP2D6 | |
| SCHEMBL3275205 | 0.75 | GSK3B (0.41) | GSK3BNPC1RAB9ACYP2D6 | |
| SCHEMBL3273975 | 0.75 | GSK3B (0.47) | GSK3BCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2160387-B1 | HETEROARYLAMIDE PYRIMIDONE COMPOUNDS | SANOFI SA (FR) | 2014-05-14 | — | — | EP | claimed |
| EP-2160387-A2 | HETEROARYLAMIDE PYRIMIDONE COMPOUNDS | Sanofi-Aventis (FR) | 2010-03-10 | — | — | EP | claimed |
| WO-2008155668-A2 | HETEROARYLAMIDE PYRIMIDONE COMPOUNDS | SANOFI-AVENTIS (FR) | 2008-12-24 | — | — | WO | claimed |
| EP-1992624-A1 | Heteroarylamide pyrimidone compounds | Sanofi-Aventis (FR) | 2008-11-19 | — | — | EP | claimed |
| EP-2160387-B1 | HETEROARYLAMIDE PYRIMIDONE COMPOUNDS | SANOFI SA (FR) | 2014-05-14 | — | — | EP | disclosed |
| US-8592437-B2 | Heteroarylamide pyrimidone compounds | SANOFI (FR) | 2013-11-26 | — | — | US | disclosed |
| US-20100087449-A1 | HETEROARYLAMIDE PYRIMIDONE COMPOUNDS | SANOFI-AVENTIS (FR) | 2010-04-08 | — | — | US | disclosed |
| EP-2160387-A2 | HETEROARYLAMIDE PYRIMIDONE COMPOUNDS | Sanofi-Aventis (FR) | 2010-03-10 | — | — | EP | disclosed |
| WO-2008155668-A2 | HETEROARYLAMIDE PYRIMIDONE COMPOUNDS | SANOFI-AVENTIS (FR) | 2008-12-24 | — | — | WO | disclosed |
| EP-1992624-A1 | Heteroarylamide pyrimidone compounds | Sanofi-Aventis (FR) | 2008-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087449-A1 | HETEROARYLAMIDE PYRIMIDONE COMPOUNDS | DHFR, DPYD, HPRT1 | GSK3B 2561/4885NPC1 725/4885RAB9A 1993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.